Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLP-HPV-01 therapeutic vaccination for HPV16-positive high-grade anal intraepithelial neoplasia in HIV-positive men
NL-OMON41467Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2013
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SLP-HPV-01 in anal intraepithelial neoplasia (AIN) and HPV16 infection (HPV16), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety and toxicity, Lesion regression at 3 months and 2 more. Started Aug 2013; status: active, not recruiting.
02
Drugs
SLP-HPV-01
03
Conditions
anal intraepithelial neoplasia (AIN)HPV16 infection (HPV16)
Beyond the preview
Go deeper on NL-OMON41467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41467.